pegozafermin

News

Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.

News

Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.